

Since this is a very extensive table, the format and content has not been edited by ActaDV.

Table SII. Literature review of methotrexate (MTX) in the treatment of pityriasis rubra pilaris

M/F	Age, years	MTX dosage, mg	MTX route	MTX duration	Improvement	Effect	Patients	Reliability	Adverse reactions	Pretreatment	Remarks	References	Year
<i>Positive results</i>													
–	–	–	–	–	Any improvement	1–4	17	Low				6	1980
5/3	35–74	10–25 in 1 or 3 doses/week	–	2–12 (6) months	Cleared	1	8	High		3× ISO, 3× VIT-A		13	1994
6/0	40–60	12.5–75/week	1× i.v., 1× i.m., Later all p.o.	16–83 (42.7) weeks	Cleared	1	6	High	1× oral ulcers + GIT 1× mild leucopaenia	2× GCS, 2× VIT-A	1× VIT-A with MTX	7	1970
–	45–87	15–25/week	4× i.m., 1× p.o.	4.5–19.5 (12.1) months	Cleared	1	2	High	1× mild cytolysis	2× ACI		8	1999
					Partial improvement	3	3	High					
2/2	20–60	27.5–40/week	p.o.	13–38 (22) weeks	Significant improvement	2	3	High		4× VIT-A, 1× VIT-E, 1× GCS	3× childhood onset	9	1972
		7.5–20/week	p.o.	6 weeks	Slight improvement	4	1	High	GIT				
3/0	50–83	10–25/week	s.c.	6–22 (14) months	Almost cleared	2	3	High	2× LFP	1× ADA, ACI, 1× GCS			Our data
0/3	11–13	2.5/day	p.o.	3 months	Cleared	1	1	High			all childhood onset	10	1969
		5/day	p.o.	3x 6 weeks (in 8 months)	Almost cleared	2	1	High			2× VIT-A with MTX		
		5/day	p.o.	4 weeks + 6 weeks	Slight improvement	4	1	High	1× oral ulcers				
2/0	53 + 80	7.5–20/week	–	–	Cleared	1	2	Low				37	2014
2/0	57 + 58	2.5 and 5/day alternately	p.o.	12–15 (13.5) months	Almost cleared	2	2	High	1× leucopaenia			2	1966
–	–	10–15/week	–	25 months	Cleared	1	1	High		1× GCS		27	1991
			p.o.	2 months	Improved	3	1	High					
1/0	66	2.5/day	p.o.	3 weeks	Marked improvement	2	1	High		1× VIT-A		11	1966
0/1	82	7.5/week	p.o.	6 months	Dramatic resolution	2	1	High		1× ACI	Ectropion cured	14	2007
1/0	64	2.5/4–6 day/week	p.o.	5+ months	Considerable improvement	2	1	High	LFP			15	2013
1/0	33	7.5–15/week	–	6+ months	Marked	3	1	High		RET, ETR,		16	1995

					improvement					ACI, AZA, GCS				
1/0	18	2.5– 5/day/alternate week	p.o.	4 months	Considerable improvement	2	1	High			Childhood onset	17	1966	
1/0	24	25–50/week	p.o., later i.v.	5 years	95% clear	2	1	High	Neutropaenia	VIT-A, MMF	Childhood onset	12	1983	
1/0	18	Up to 30/week	p.o.	?	Partial improvement	3	1	Low		ETR, re- PUVA, HYD		21	1998	
1/0	67	5/5 day/week	p.o.	6 months	Improved	3	1	Low	Pneumonia			19	1998	
0/1	34	Up to 20/week	–	–	Good improvement	3	1	Low				39	2010	
0/1	59	7.5–15/week	p.o.	5 months	Slight improvement	4	1	High				18	2006	
<i>Negative results</i>														
–	–	–	–	–	No response	5	27	Low				6	1980	
–	Children	–	–	–	No favourable response	5	5	Low			Childhood onset	23	2002	
0/1	63	2.5/day	p.o.	2 weeks	No improvement	5	1	High		VIT-A		24	1964	
–	–	3× 50/12–14 days	–	6 weeks	No improvement	5	1	High				25	1972	
0/1	74	15/week	s.c.	1–2 months	No significant effect	5	1	High	1× GIT	GCS, ACI, CYC	ADA+ALI subsequently	26	2011	
–	–	10–15/week	–	3 months	No improvement	5	1	High		1× GCS	Retinoid subsequently	27	1991	
0/1	33	–	–	–	No improvement	5	1	Low		"retinoids", CYC	Childhood- onset	28	2008	
0/1	65	15–30/week	i.v.	–	No improvement	5	1	Low		GCS		29	2009	
<i>Double therapy</i>														
9/2	35–68	5–30/week	p.o.	2–22 (11,4) months	Cleared	1	5	High	2× GIT	11× ETR (2× +ISO)	5× failed on retinoid monotherapy	20	1997	
				3–14 (7,6) months	95% clear	2	5	High						
				7 months	No improvement	5	1	High						
2/0	62 + 66	20/week	–	–	Cleared	1	2	Low		ACI		37	2014	
1/0	77	Up to 20/week	–	–	Mixed response	4	1	Low		FUM		39	2010	
1/0	60	2.5 and 5/day alternately	p.o.	12 months	Almost cleared	2	1	High	1× leucopaenia	VIT-A		2	1966	
0/1	36	22.5/week	–	–	No improvement	5	1	Low		ISO	HIV+ / AIDS	38	1997	

"Improvement" lists the treatment effect stated in the particular studies. "Effect" lists the treatment response categorized into 1 for "total clearance", 2 for "excellent improvement", 3 for "partial improvement", 4 for "slight improvement" and 5 for "no improvement". Adverse reactions: GIT: gastrointestinal side-effects; LFP: elevated liver function parameters"; prior treatment and concurrent treatment: ADA: adalimumab, ACI: acitretin, ALI: alitretinoin, AZA: azathioprine, CYC: cyclosporine, ETR: etretinate, FUM: fumaric acid, GCS: systemic glucocorticoids, HYD: hydroxyurea, ISO: isotretinoin, MMF: mycophenolic acid, MTX: methotrexate, RET: retinoic acid, VIT-A: vitamin A, VIT-E: vitamin E.